000130504 001__ 130504
000130504 005__ 20240228143439.0
000130504 0247_ $$2doi$$a10.1016/j.ijrobp.2015.10.058
000130504 0247_ $$2pmid$$apmid:26853341
000130504 0247_ $$2ISSN$$a0360-3016
000130504 0247_ $$2ISSN$$a1879-355X
000130504 0247_ $$2altmetric$$aaltmetric:4716534
000130504 037__ $$aDKFZ-2017-05583
000130504 041__ $$aeng
000130504 082__ $$a610
000130504 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000130504 245__ $$aResistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial.
000130504 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2016
000130504 3367_ $$2DRIVER$$aarticle
000130504 3367_ $$2DataCite$$aOutput Types/Journal article
000130504 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524812027_6736
000130504 3367_ $$2BibTeX$$aARTICLE
000130504 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130504 3367_ $$00$$2EndNote$$aJournal Article
000130504 520__ $$aTo explore the mediating role of inflammatory parameters in the development of fatigue, pain, and potentially related depressive symptoms during radiation therapy for breast cancer and its mitigation by resistance exercise.Breast cancer patients scheduled for adjuvant radiation therapy were randomized to 12-week progressive resistance exercise training (EX) or a relaxation control group. Interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1ra) were measured in serum samples collected before, at the end, and 6 weeks after radiation therapy from 103 chemotherapy-naïve participants. Fatigue was assessed with the multidimensional Fatigue Assessment Questionnaire, pain with the European Organization for Research and Treatment of Cancer QLQ-C30, and depressive symptoms with the Center for Epidemiologic Studies Depression Scale. Analysis of covariance models, partial correlations, Freedman-Schatzkin tests, and R(2) effect-size measures for mediation were calculated.The analysis of covariance models revealed a significant intervention effect on IL-6 (P=.010) and the IL-6/IL-1ra ratio (P=.018), characterized by a marked increase during radiation therapy among controls, but no significant change in EX. Interleukin-1 receptor antagonist did not change significantly in either group (P=.88). Increased IL-6 and IL-6/IL-1ra levels at the end of radiation therapy were significantly associated with increased physical fatigue and pain 6 weeks after radiation. We observed significant partial mediation by IL-6 and IL-6/IL-1ra of the effect of resistance exercise on physical fatigue (Freedman-Schatzkin P=.023 and P<.001) and pain (both P<.001). Hereby IL-6 and IL-6/IL-1ra mediated between 15% and 24% of the variance of physical fatigue and pain explained by the intervention.This randomized, controlled trial showed a significantly increased proinflammatory cytokine level after adjuvant radiation therapy in breast cancer patients. This effect was counteracted by progressive resistance exercise training. Interleukin-6 and the IL-6/IL-1ra ratio seemed to mediate the beneficial effect of exercise on physical fatigue and pain but only to a small extent.
000130504 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130504 588__ $$aDataset connected to CrossRef, PubMed,
000130504 650_7 $$2NLM Chemicals$$aInterleukin-6
000130504 650_7 $$2NLM Chemicals$$aReceptors, Interleukin-1 Type I
000130504 7001_ $$0P:(DE-HGF)0$$aMeynköhn, Anna$$b1
000130504 7001_ $$0P:(DE-HGF)0$$aHabermann, Nina$$b2
000130504 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b3$$udkfz
000130504 7001_ $$aOelmann, Jan$$b4
000130504 7001_ $$aHof, Holger$$b5
000130504 7001_ $$aWessels, Sabine$$b6
000130504 7001_ $$0P:(DE-HGF)0$$aKlassen, Oliver$$b7
000130504 7001_ $$aDebus, Jürgen$$b8
000130504 7001_ $$0P:(DE-HGF)0$$aPotthoff, Karin$$b9
000130504 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b10$$eLast author$$udkfz
000130504 7001_ $$0P:(DE-HGF)0$$aUlrich, Cornelia M$$b11$$eLast author
000130504 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2015.10.058$$gVol. 94, no. 2, p. 329 - 337$$n2$$p329 - 337$$tInternational journal of radiation oncology, biology, physics$$v94$$x0360-3016$$y2016
000130504 909CO $$ooai:inrepo02.dkfz.de:130504$$pVDB
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130504 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130504 9141_ $$y2016
000130504 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130504 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2015
000130504 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130504 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130504 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130504 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130504 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130504 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130504 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130504 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130504 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130504 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130504 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130504 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130504 9201_ $$0I:(DE-He78)G111-20160331$$kG111$$lBewegung, Sport und Krebs$$x0
000130504 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000130504 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x2
000130504 980__ $$ajournal
000130504 980__ $$aVDB
000130504 980__ $$aI:(DE-He78)G111-20160331
000130504 980__ $$aI:(DE-He78)G110-20160331
000130504 980__ $$aI:(DE-He78)G210-20160331
000130504 980__ $$aUNRESTRICTED